Molecular docking and receptor-specific 3D-QSAR studies of acetylcholinesterase inhibitors

The reversible inhibition of acetylcholinesterase (AChE) has become a promising target for the treatment of Alzheimer’s disease (AD) which is mainly associated with low in vivo levels of acetylcholine (ACh). The availability of AChE crystal structures with and without a ligand triggered the effort to find a structure-based design of acetylcholinesterase inhibitors (AChEIs) for AD. The major problem observed with the structure-based design was the feeble robustness of the scoring functions toward the correlation of docking scores with inhibitory potencies of known ligands. This prompted us to develop new prediction models using the stepwise regression analysis based on consensus of different docking and their scoring methods (GOLD, LigandFit, and GLIDE). In the present investigation, a dataset of 91 molecules belonging to 9 different structural classes of heterocyclic compounds with an activity range of 0.008 to 281,000 nM was considered for docking studies and development of AChE-specific 3D-QSAR models. The model (M1) developed using consensus of docking scores of scoring functions viz. Glide score, Gold score, Chem score, ASP score, PMF score, and DOCK score was found to be the best (R2 = 0.938, Q2 = 0.925,R2pred = 0.919,R2m(overall) = 0.936) compared to other consensus models. Docking studies revealed that the molecules with proper alignment in the active site gorge and the ability to interact with all the crucial amino acid residues, in particular by forming π–π stacking interactions with Trp84 at the catalytic anionic site (CAS) and Trp279 at peripheral anionic site (PAS), showed augmented potencies with consequent improvement in patient cognition and reduced the formation of senile plaques associated with AD. Further, the descriptors that signify the association of the ligands with the receptor as well as ADME properties of the ligands were also analyzed by means of the set of ligands that have been pre-positioned with respect to a receptor after docking analysis and considered as independent variables to generate a linear model (M3 and M4) using a stepwise multiple linear regression method to get additional insight into the physicochemical requirements for effective binding of ligands with AChE as well as for prediction of AChE inhibition. The developed AChE-specific prediction models (M1–M4) satisfactorily reflect the structure–activity relationship of the existing AChEIs and have all the potential to facilitate the process of design and development of new potent AChEIs.

[1]  Gennady M Verkhivker,et al.  Molecular recognition of the inhibitor AG-1343 by HIV-1 protease: conformationally flexible docking by evolutionary programming. , 1995, Chemistry & biology.

[2]  B. Everitt,et al.  Cluster Analysis: Low Temperatures and Voting in Congress , 2001 .

[3]  F. J. Luque,et al.  Novel donepezil-based inhibitors of acetyl- and butyrylcholinesterase and acetylcholinesterase-induced beta-amyloid aggregation. , 2008, Journal of medicinal chemistry.

[4]  D. Selkoe,et al.  Translating cell biology into therapeutic advances in Alzheimer's disease , 1999, Nature.

[5]  C. Venkatachalam,et al.  LigScore: a novel scoring function for predicting binding affinities. , 2005, Journal of molecular graphics & modelling.

[6]  I. Kuntz,et al.  Automated docking with grid‐based energy evaluation , 1992 .

[7]  David W McClymont,et al.  Inhibition of acetylcholinesterase, beta-amyloid aggregation, and NMDA receptors in Alzheimer's disease: a promising direction for the multi-target-directed ligands gold rush. , 2008, Journal of medicinal chemistry.

[8]  K. Roy,et al.  Quantitative Structure–Activity Relationship Modeling of Antioxidant Activities of Hydroxybenzalacetones Using Quantum Chemical, Physicochemical and Spatial Descriptors , 2009, Chemical biology & drug design.

[9]  Gerald H Lushington,et al.  A docking score function for estimating ligand-protein interactions: application to acetylcholinesterase inhibition. , 2004, Journal of medicinal chemistry.

[10]  J L Sussman,et al.  A structure-based design approach to the development of novel, reversible AChE inhibitors. , 2001, Journal of medicinal chemistry.

[11]  Joel L Sussman,et al.  The complex of a bivalent derivative of galanthamine with torpedo acetylcholinesterase displays drastic deformation of the active-site gorge: implications for structure-based drug design. , 2004, Journal of the American Chemical Society.

[12]  F. LaFerla,et al.  Alzheimer's disease. , 2010, The New England journal of medicine.

[13]  Jana Sopkova-de Oliveira Santos,et al.  Virtual Screening Discovery of New Acetylcholinesterase Inhibitors Issued from CERMN Chemical Library , 2010, J. Chem. Inf. Model..

[14]  N. Ariel,et al.  Structures of recombinant native and E202Q mutant human acetylcholinesterase complexed with the snake-venom toxin fasciculin-II. , 2000, Acta crystallographica. Section D, Biological crystallography.

[15]  J. Sussman,et al.  Structure of acetylcholinesterase complexed with E2020 (Aricept): implications for the design of new anti-Alzheimer drugs. , 1999, Structure.

[16]  V. Andrisano,et al.  Benzofuran-based hybrid compounds for the inhibition of cholinesterase activity, beta amyloid aggregation, and abeta neurotoxicity. , 2008, Journal of medicinal chemistry.

[17]  P. Roy,et al.  On Some Aspects of Variable Selection for Partial Least Squares Regression Models , 2008 .

[18]  Yuan-Ping Pang,et al.  Complexes of alkylene-linked tacrine dimers with Torpedo californica acetylcholinesterase: Binding of Bis5-tacrine produces a dramatic rearrangement in the active-site gorge. , 2006, Journal of medicinal chemistry.

[19]  C. Pérez,et al.  Novel tacrine-melatonin hybrids as dual-acting drugs for Alzheimer disease, with improved acetylcholinesterase inhibitory and antioxidant properties. , 2006, Journal of medicinal chemistry.

[20]  P. Masson,et al.  Structural evidence that human acetylcholinesterase inhibited by tabun ages through O-dealkylation. , 2010, Journal of medicinal chemistry.

[21]  J. Sussman,et al.  Quaternary ligand binding to aromatic residues in the active-site gorge of acetylcholinesterase. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[22]  Yuan-Ping Pang,et al.  Structure of acetylcholinesterase complexed with the nootropic alkaloid, (–)-huperzine A , 1997, Nature Structural Biology.

[23]  Kaki Venkata Rao,et al.  Molecular Modeling Evaluation of Non‐Steroidal Aromatase Inhibitors † , 2012, Chemical biology & drug design.

[24]  J L Sussman,et al.  Static Laue diffraction studies on acetylcholinesterase. , 1998, Acta crystallographica. Section D, Biological crystallography.

[25]  N. Greig,et al.  Inhibition of human acetyl- and butyrylcholinesterase by novel carbamates of (-)- and (+)-tetrahydrofurobenzofuran and methanobenzodioxepine. , 2006, Journal of medicinal chemistry.

[26]  Matthew P. Repasky,et al.  Glide: a new approach for rapid, accurate docking and scoring. 1. Method and assessment of docking accuracy. , 2004, Journal of medicinal chemistry.

[27]  Kunal Roy,et al.  Exploring 2D and 3D QSARs of 2,4-diphenyl-1,3-oxazolines for ovicidal activity against Tetranychus urticae , 2009 .

[28]  Marcel L Verdonk,et al.  General and targeted statistical potentials for protein–ligand interactions , 2005, Proteins.

[29]  G. V. Paolini,et al.  Empirical scoring functions: I. The development of a fast empirical scoring function to estimate the binding affinity of ligands in receptor complexes , 1997, J. Comput. Aided Mol. Des..

[30]  Rita Santos,et al.  Role of Water in Molecular Docking Simulations of Cytochrome P450 2D6 , 2010, J. Chem. Inf. Model..

[31]  C. Pérez,et al.  Novel tacrine-8-hydroxyquinoline hybrids as multifunctional agents for the treatment of Alzheimer's disease, with neuroprotective, cholinergic, antioxidant, and copper-complexing properties. , 2010, Journal of medicinal chemistry.

[32]  M. Giovannini,et al.  Cholinesterase inhibitors and beyond. , 2009, Current Alzheimer research.

[33]  N. Inestrosa,et al.  Amyloid–cholinesterase interactions , 2008, The FEBS journal.

[34]  V. Papadopoulos,et al.  3D QSAR studies of AChE inhibitors based on molecular docking scores and CoMFA. , 2006, Bioorganic & medicinal chemistry letters.

[35]  Ajay N. Jain,et al.  Scoring functions for protein-ligand docking. , 2006, Current protein & peptide science.

[36]  J. Sussman,et al.  Acetylcholinesterase: how is structure related to function? , 2008, Chemico-biological interactions.

[37]  I. Muegge.  PMF scoring revisited. , 2006, Journal of medicinal chemistry.

[38]  A. Goldman,et al.  Atomic structure of acetylcholinesterase from Torpedo californica: a prototypic acetylcholine-binding protein , 1991, Science.

[39]  Hege S. Beard,et al.  Glide: a new approach for rapid, accurate docking and scoring. 2. Enrichment factors in database screening. , 2004, Journal of medicinal chemistry.

[40]  Kunal Roy,et al.  On some aspects of validation of predictive quantitative structure–activity relationship models , 2007, Expert opinion on drug discovery.

[41]  J L Sussman,et al.  Structure of acetylcholinesterase complexed with (−)‐galanthamine at 2.3 Å resolution , 1999, FEBS letters.

[42]  R. Darlington,et al.  Regression and Linear Models , 1990 .

[43]  V. Andrisano,et al.  beta-Amyloid aggregation induced by human acetylcholinesterase: inhibition studies. , 2003, Biochemical pharmacology.

[44]  N. Greig,et al.  Current drug targets for Alzheimer's disease treatment , 2002 .

[45]  A. Cavalli,et al.  Design, synthesis, and biological evaluation of conformationally restricted rivastigmine analogues. , 2004, Journal of medicinal chemistry.

[46]  J. Sussman,et al.  Reaction Products of Acetylcholinesterase and VX Reveal a Mobile Histidine in the Catalytic Triad , 1999 .

[47]  Shikha Gupta,et al.  3D-pharmacophore model based virtual screening to identify dual-binding site and selective acetylcholinesterase inhibitors , 2011, Medicinal Chemistry Research.

[48]  Aamir Nazir,et al.  Novel carbamates as orally active acetylcholinesterase inhibitors found to improve scopolamine-induced cognition impairment: pharmacophore-based virtual screening, synthesis, and pharmacology. , 2010, Journal of medicinal chemistry.

[49]  P Willett,et al.  Development and validation of a genetic algorithm for flexible docking. , 1997, Journal of molecular biology.

[50]  A. Cavalli,et al.  Structure-activity relationships of acetylcholinesterase noncovalent inhibitors based on a polyamine backbone. 4. Further investigation on the inner spacer. , 2008, Journal of medicinal chemistry.

[51]  N. Inestrosa,et al.  Acetylcholinesterase-Aβ Complexes Are More Toxic than Aβ Fibrils in Rat Hippocampus : Effect on Rat β-Amyloid Aggregation, Laminin Expression, Reactive Astrocytosis, and Neuronal Cell Loss , 2004 .

[52]  David A. Smith.  Treatment of Alzheimer's disease in the long-term-care setting. , 2009, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.

[53]  P. Roy,et al.  QSAR of adenosine receptor antagonists: Exploring physicochemical requirements for binding of pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidine derivatives with human adenosine A(3) receptor subtype. , 2011, Bioorganic & medicinal chemistry letters.

[54]  J. Sussman,et al.  The X-ray structure of a transition state analog complex reveals the molecular origins of the catalytic power and substrate specificity of acetylcholinesterase. , 1996 .

[55]  Ana Martínez,et al.  Targeting beta-amyloid pathogenesis through acetylcholinesterase inhibitors. , 2006, Current pharmaceutical design.

[56]  Xavier Barril,et al.  Tacripyrines, the first tacrine-dihydropyridine hybrids, as multitarget-directed ligands for the treatment of Alzheimer's disease. , 2009, Journal of medicinal chemistry.

[57]  Brian Everitt,et al.  Cluster analysis , 1974 .